The Dual-Specificity Phosphatase 10 (DUSP10): Its Role in Cancer, Inflammation, and Immunity

Jiménez-Martínez, Marta; Stamatakis, Konstantinos; Fresno, Manuel

doi:10.3390/ijms20071626

Cited by 47 publications

(38 citation statements)

References 66 publications

(92 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonetheless, it would be interesting to further explore this aspect through future analyses to compare gene expression between individuals carrying the risk variant and control individuals. Previous studies have pointed in the same direction that there is overall increase in patients’ relapse-free survival when DUSP10 expression is upregulated, and that DUSP10 mRNA was increased in the tumour compared with normal tissue adjacent to the tumours [46,49,50].…”

Section: Discussionmentioning

confidence: 96%

Single nucleotide polymorphisms associated with susceptibility for development of colorectal cancer: Case-control study in a Basque population

et al. 2019

View full text Add to dashboard Cite

Given the significant population diversity in genetic variation, we aimed to investigate whether single nucleotide polymorphisms (SNPs) previously identified in studies of colorectal cancer (CRC) susceptibility were also relevant to the population of the Basque Country (North of Spain). We genotyped 230 CRC cases and 230 healthy controls for 48 previously reported CRC-susceptibility SNPs. Only the rs6687758 in DUPS10 exhibited a statistically significant association with CRC risk based on the crude analysis. The rs6687758 AG genotype conferred about 2.13-fold increased risk for CRC compared to the AA genotype. Moreover, we found significant associations in cases between smoking status, physical activity, and the rs6687758 SNP. The results of a Genetic Risk Score (GRS) showed that the risk alleles were more frequent in cases than controls and the score was associated with CRC in crude analysis. In conclusion, we have confirmed a CRC susceptibility locus and the existence of associations between modifiable factors and the rs6687758 SNP; moreover, the GRS was associated with CRC. However, further experimental validations are needed to establish the role of this SNP, the function of the gene identified, as well as the contribution of the interaction between environmental factors and this locusto the risk of CRC.

show abstract

Section: Discussionmentioning

confidence: 96%

Single nucleotide polymorphisms associated with susceptibility for development of colorectal cancer: Case-control study in a Basque population

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Until recently, there were few reports regarding the putative role of DUSP10 in cancer. Most of those studies have found increased DUSP10 mRNA in tumor tissue, thus suggesting a pro-tumorigenic role for this phosphatase (Jimenez-Martinez et al, 2019b). In CRC, the expression of certain DUSP10 polymorphisms are linked to an enhanced CRC risk (Duan et al, 2015).…”

Section: Dual-specificity Mapk Phosphatase 10mentioning

confidence: 99%

Cyclooxygenase 2-Regulated Genes an Alternative Avenue to the Development of New Therapeutic Drugs for Colorectal Cancer

et al. 2020

Self Cite

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most common and recurrent types of cancer, with high mortality rates. Several clinical trials and meta-analyses have determined that the use of pharmacological inhibitors of cyclooxygenase 2 (COX-2), the enzyme that catalyses the rate-limiting step in the synthesis of prostaglandins (PG) from arachidonic acid, can reduce the incidence of CRC as well as the risk of recurrence of this disease, when used together with commonly used chemotherapeutic agents. These observations suggest that inhibition of COX-2 may be useful in the treatment of CRC, although the current drugs targeting COX-2 are not widely used since they increase the risk of health complications. To overcome this difficulty, a possibility is to identify genes regulated by COX-2 activity that could give an advantage to the cells to form tumors and/or metastasize. The modulation of those genes as effectors of COX-2 may cancel the beneficial effects of COX-2 in tumor transformation and metastasis. A review of the available databases and literature and our own data have identified some interesting molecules induced by prostaglandins or COX-2 that have been also described to play a role in colon cancer, being thus potential pharmacological targets in colon cancer. Among those mPGES-1, DUSP4, and 10, Programmed cell death 4, Trop2, and many from the TGFb and p53 pathways have been identified as genes upregulated in response to COX-2 overexpression or PGs in colon carcinoma lines and overexpressed in colon tumor tissue. Here, we review the available evidence of the potential roles of those molecules in colon cancer in the context of PG/ COX signaling pathways that could be critical mediators of some of the tumor growth and metastasis advantage induced by COX-2. At the end, this may allow defining new therapeutic targets/drugs against CRC that could act specifically against tumor cells and would be effective in the prevention and treatment of CRC, lacking the unwanted side effects of COX-2 pharmacological inhibitors, providing alternative approaches in colon cancer.

show abstract

“…However, it may regulate other targets such as interferon regulatory ractor 3 (IRF3) and extracellular signal-regulated kinase (ERK) by dephosphorylation or association, respectively [13,14]. Recently, DUSP10 has been proposed as regulator of inflammation, immunity, and cancer [15]; although its involvement remains to be explored and confirmed.…”

Section: Introductionmentioning

confidence: 99%

DUSP10 Is a Regulator of YAP1 Activity Promoting Cell Proliferation and Colorectal Cancer Progression

Jiménez-Martínez

Ostalé

Burg

et al. 2019

Cancers

Self Cite

View full text Add to dashboard Cite

Cell contact inhibition (CCI) is deregulated in cancer. Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide. We found that dual-specificity phosphatase 10 (DUSP10) is involved in CRC. DUSP10 overexpression increased the growth of CRC cell lines and mouse xenografts, while the opposite phenotype was observed by DUSP10 silencing. High cell density (HD) induced DUSP10 expression in CRC cell lines, particularly within the nucleus. Yes-associated protein 1 (YAP1) is activated by dephosphorylation, controlling organ growth and CCI, both processes being deregulated in CRC. Expression levels and localization of DUSP10 matched with YAP1 levels in CRC cell lines. DUSP10 and YAP1 co-immunoprecipitated and their interaction was dependent on YAP1 Ser397. The existence of DUSP10 and YAP1 pathway in vivo was confirmed by using a transgenic Drosophila model. Finally, in CRC patients’ samples, high levels of nuclear DUSP10 correlated with nuclear YAP1 in epithelial tumor tissue. Strong nuclear DUSP10 staining also correlated with high tumor stage and poor survival. Overall, these findings describe a DUSP10–YAP1 molecular link in CRC cell lines promoting cell growth in HD. We present evidence suggesting a pro-tumorigenic role of nuclear DUSP10 expression in CRC patients.

show abstract

The Dual-Specificity Phosphatase 10 (DUSP10): Its Role in Cancer, Inflammation, and Immunity

Cited by 47 publications

References 66 publications

Single nucleotide polymorphisms associated with susceptibility for development of colorectal cancer: Case-control study in a Basque population

Single nucleotide polymorphisms associated with susceptibility for development of colorectal cancer: Case-control study in a Basque population

Cyclooxygenase 2-Regulated Genes an Alternative Avenue to the Development of New Therapeutic Drugs for Colorectal Cancer

DUSP10 Is a Regulator of YAP1 Activity Promoting Cell Proliferation and Colorectal Cancer Progression

Contact Info

Product

Resources

About